Compare Huntington Ingalls Industries Inc (HII) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Ingalls Industries Inc vs Incyte Corporation — how do they compare? Huntington Ingalls Industries Inc trades at $272.08 (market cap $10.64B), while Incyte Corporation trades at $115.71 (market cap $23.11B). The key difference: Incyte Corporation is far larger — about 2.2× Huntington Ingalls Industries Inc's market cap, and Huntington Ingalls Industries Inc pays a 2.04% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| HII | INCY | |
|---|---|---|
Market Cap | $10.64B | $23.11B |
Sector | Technology | Health |
52-Week High | $453.73 | $118.52 |
52-Week Low | $252.93 | $67.38 |
Enterprise Value | $13.36B | $19.13B |
Dividend Yield | 2.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HII trades at $270.04, up 0.34% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company shows solid fundamentals with a P/E of 17.49 and ROE of 12.2%, supported by three consecutive quarterly earnings beats. Recent news highlights contract wins and shipbuilding milestones, reinforcing its defense sector presence. Cash flow improved to a net positive $49 million in 2026 from a net outflow of $57 million in 2025.
The outlook is cautiously optimistic given analyst consensus targets near $354.50, though technical resistance at $273 poses a near-term hurdle. Risks include execution delays on defense contracts and macroeconomic pressures on government spending. The stock offers value with a below-sector P/S of 0.82, but investors should monitor Q2 2026 earnings due July 30 for margin sustainability.
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
